Clinical Study of Visibility Tinted Clariti Contact Lens

NCT ID: NCT01996787

Last Updated: 2013-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to investigate the safety and efficacy of the Sauflon Clariti Monthly silicone hydrogel contact lenses with handling tint (Sauflon Pharmaceuticals Limited) by comparison with Air Optix Aqua silicone hydrogel lenses (Alcon Inc.)

Subjects used OptiFree Replenish solution (Alcon Lboratories Inc.) for daily lens maintenance, care and storage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

I. Study characteristics:

The clinical study evaluates the clinical performance of a silicone hydrogel contact lens for daily wear, Clariti (including handling tint) (Sauflon Pharmaceuticals Ltd.) versus a predicate device, Air Optix Aqua (Alcon Inc.), in terms of lens performance, physiological response and subjective acceptance.

Subjects used OptiFRee Replenish solution (Alcon Laboratories Inc.) for daily lens maintenance, care and storage.

The key features were as follows:

1. One month duration.
2. Three investigator sites.
3. Daily wear soft (hydrophilic) silicone hydrogel contact lenses, replaced on a monthly basis: Clariti Monthly (with handling tint)and Air Optix Aqua. Replenish was used as a care system by all subjects.
4. A total of 38 subjects were enrolled, and 38 subjects accounted for 76 eyes were dispensed lenses. This group was randomized into 25 test subjects (50 eyes) and 13 control subjects (26 eyes).
5. Of the 25 test subjects, 25 (100%) completed one month of use. Of the 13 control subjects, 12 (92.3%)completed one month of use.
6. There were no adverse reactions.

II. Study period:

The study was conducted over one month of wear. Subjects were examined initially, and at two follow-up visits after two weeks and four weeks respectively. Study visits commenced on June 26, 2013 and completed on September 14, 2013.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperopia Myopia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

visibility tinted silicone hydrogel contact lenses for daily wear

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Air Optix Aqua

Compare safety and efficacy of the lens using OptiFree Replenish solution

Group Type ACTIVE_COMPARATOR

Air Optix Aqua

Intervention Type DEVICE

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Clariti with Handling Tint

Intervention Type DEVICE

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Clariti with Handling Tint

Compare safety and efficacy of the lens using OptiFree Replenish solution

Group Type ACTIVE_COMPARATOR

Air Optix Aqua

Intervention Type DEVICE

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Clariti with Handling Tint

Intervention Type DEVICE

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Air Optix Aqua

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Intervention Type DEVICE

Clariti with Handling Tint

Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* They are 18 years of age and above
* They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent
* They are willing and able to follow the protocol
* The agree not to paticipate in other clinical research for the duration of this study
* They have a best spectacle corrected visual acuity greater or equal to 20/25 (logMAR 0.1)
* They have a manifest cylinder less than or equal to 0.75D
* They have successfully worn contact lenses within six months of starting the study
* They can be fitted with spherical soft contact lenses within the power range available
* They are willing to wear the study lenses for a minimum of four days a week, six hours a day

Exclusion Criteria

* They have any active anterior segment ocular disease which would normally contraindicate contact lens wear
* They have any anterior segment infection, inflammation or abnormality
* They use any systemic medications which would normally contraindicate contact lens wear
* They are using any ocular medications
* They have a history of herpetic keratitis
* They have a systemic disorder which would normally contraindicate contact lens wear
* They have any infectious disease (e.g. Hepatitis) or any immunosuppressive disease (e.g. HIV)
* They have glaucoma (high pressure in the eye), have had cataract surgery or a history of recurring abrasions
* They have had corneal refractive surgery or they have an irregular cornea
* They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus
* They are pregnant or lactating
* They have any slit lamp findings which are more serious than grade 1
* They have a history of anaphylaxis or severe allergic reactions
* They have taken part in any other contact lens or contact lens care product clinical trial or research, within two weeks prior to starting this study
Minimum Eligible Age

19 Years

Maximum Eligible Age

56 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sauflon Pharmaceuticals Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philip Morgan, PhD

Role: PRINCIPAL_INVESTIGATOR

MCOptom FAAO FBCLA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eurolens Research Faculty of Life Sciences The University of Manchester

Manchester, Manchester, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Varikooty J, Keir N, Richter D, Jones LW, Woods C, Fonn D. Comfort response of three silicone hydrogel daily disposable contact lenses. Optom Vis Sci. 2013 Sep;90(9):945-53. doi: 10.1097/OPX.0b013e31829d8dbf.

Reference Type RESULT
PMID: 23892493 (View on PubMed)

Belda-Salmeron L, Ferrer-Blasco T, Albarran-Diego C, Madrid-Costa D, Montes-Mico R. Diurnal variations in visual performance for disposable contact lenses. Optom Vis Sci. 2013 Jul;90(7):682-90. doi: 10.1097/OPX.0b013e318299088f.

Reference Type RESULT
PMID: 23770656 (View on PubMed)

Montes-Mico R, Belda-Salmeron L, Ferrer-Blasco T, Albarran-Diego C, Garcia-Lazaro S. On-eye optical quality of daily disposable contact lenses for different wearing times. Ophthalmic Physiol Opt. 2013 Sep;33(5):581-91. doi: 10.1111/opo.12044. Epub 2013 Mar 19.

Reference Type RESULT
PMID: 23510388 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://clinicaltrials.gov/ct2/show/NCT01392950?term=Clariti&rank=1

Clinical Study of Clariti Monthly Contact Lens

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S13-540

Identifier Type: -

Identifier Source: org_study_id